Pancreas · 2023 · 12 citations · 20 references
MedicineOncologyPharmacologyCancer ImmunologyDrug DeliveryTumor ImmunologyCancer Drug DeliveryCancer ImmunotherapyChemotherapy Drug AdministrationPancreatic CancerPharmacodynamics Of Anticancer AgentsPharmacokinetics Of Anticancer DrugsAdverse Drug EventsDose Escalation TherapyImmune Response CharacterizationImmunofluorescence ImagingImmunofluorescence StainingIntratumoral AdministrationPancreatic Cancer ResectionTumor Response Evaluation
OBJECTIVES: Large surface area microparticle paclitaxel (LSAM-PTX) provides an intratumoral (IT) chemotherapeutic depot. Safety, tolerability, and tumor response to IT LSAM-PTX delivered by endoscopic ultrasound-fine needle injection were evaluated in subjects with unresectable locally advanced pancreatic cancer (LAPC). METHODS: Ten subjects treated in a dose escalation phase and 22 additional subjects receiving 2 injections, 4 weeks apart, of 15 mg/mL LSAM-PTX were followed for 12 months. Paclitaxel pharmacokinetics were evaluated, imaging at 3 and 6 months determined tumor response, and multiplex immunofluorescence was conducted to characterize local immune response. RESULTS: Most treatment-emergent adverse events were attributed to LAPC. Plasma paclitaxel levels were negligible. Eight subjects' tumors became resectable after IT LSAM-PTX, and 5 of 6 (83%) were resected with R0. Multiplex immunofluorescence of resected tumors demonstrated increased T cells, natural killer cells, and macrophages and decreased myeloid-derived suppressor cells. Six-month disease control rate was 94%, and median overall survival was 19.7 months in the 2-injection subjects. For nonresected and resected groups, overall survival times were 18.9 and 35.2 months, respectively. CONCLUSIONS: Neoadjuvant IT LSAM-PTX, in combination with SOC, was well tolerated and may provide benefits to LAPC patients, evidenced by enhanced immune response, improved disease control rate, restaging leading to surgery, and extended survival.
20
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida, Siân Jones, Ivana Božić et al. · Nature · 2010 · 2.5K citations
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
Matteo Ligorio, Srinjoy Sil, Jose Malagon-Lopez et al. · Cell · 2019 · 532 citations · Full text
Medicine, Cell Biology, Oncology +17
David Nyman, Kimberley J. Campbell, Evan M. Hersh et al. · Journal of Clinical Oncology · 2005 · 281 citations · Full text
Medicine, Oncology, Pharmacology +14